49 results about "Continuous cell line" patented technology

The invention provides new strains of the Modified Vaccinia Virus Ankara (MVA) that have a strongly reduced virulence for most mammals, especially humans, but nevertheless grows in cells of a continuous cell line approved for the production of a therapeutic agent such as a vaccine. The invention also provides a method for producing said adapted MVA strains. The adapted MVA can be used e.g. for parenteral immunization, as a vector system, or in the active or inactivated from as an adjuvant or as a regulator of the unspecific components of the immune system.

The subject invention pertains to tumor cell lines useful for increasing the proliferation potential of any human or animal cell in culture, thereby providing immortalized or continuous cell lines and cultures. The invention also concerns proliferation factors, and compositions containing the factors, which are capable of increasing the proliferation potential of any human or other animal cell in culture. The subject invention further pertains to a method for proliferation cells in culture by contacting cells with the proliferation factors. The proliferated cells can range in plasticity and can include, for example, blast cells, fertilized ova, non-fertilized gametes, embryonic stem cells, adult stem cells, precursor or progenitor cells, and highly specialized cells. Optionally, the cells can be induced to cease proliferation. The proliferation cells of the subject invention are useful for cell therapy, cell / gene therapy, biological production of molecules, and as in vitro models for research, toxicity testing, and drug development.

The invention relates to a method for producing avian adenovirus inactivated vaccine through an LMH clone line. The method comprises the following steps: firstly, preparation continuous cell line LMH cell; secondly, virus-seed reproduction; thirdly, virus collection, concentration and purification; fourthly, virus content determination; fifthly, inactivation and emulsification of virus, and forming emulsion inactivated vaccine. Compared with the traditional technical method for producing avian adenovirus through cell culture, the method has the advantages that high-quality inactivated vaccine with higher antigen titer through the optimization of the concentration of digestive LMH cell pancreatin-EDTA, the culture time of LMH cell and the inoculation concentration and harvest time of virus, injection immunization is performed at different doses, and all the vaccine protection rates reach 100 percent, so that the immune efficiency of the avian adenovirus type IV inactivated vaccine produced through the method is high, and the vaccine has complete immune protection effect on avian adenovirus type IV.

Continuous cell lines that are highly permissive to infection by porcine circovirus type 2 (“PCV2”) are described. PCV2 is the causal agent of post-weaning multi-systemic wasting syndrome (“PMWS”) in pigs. PMWS has emerged as a major disease that poses a significant threat to the economics of global swine industry. The highly permissive cell lines of this invention provide efficient and reliable sources of PCV2 for use in development of vaccines, therapies and diagnostic agents for PMWS.

The invention discloses a preparation method and product of a swine fever live vaccine. The preparation method comprises the following steps: (1) culturing a swine-derived continuous cell line; (2) inoculating the swine-derived continuous cell line into a seed virus for producing the swine fever live vaccine, thereby obtaining a swine fever weak-virus vaccine strain; (3) carrying out virus multiplication on the swine fever weak-virus vaccine strain; (4) determining the virus value of the multiplied virus suspension by an immunofluorescence method; and (5) adding a freeze-drying protective agent and antibiotics into the qualified virus suspension to carry out vaccine preparation and freeze-drying. Since the swine fever live vaccine is prepared from the cell line, the difference of quality among different batches is small, and the invention has the characteristics of simple and stable technique, high yield, low cost and the like, is easy to operate, and has feasibility and amplification of industrialized mass production. In addition, the immunofluorescence method, which has the advantages of high detection sensitivity, high speed, high specificity, high accuracy, high repetitiveness and reliable result, is used for determining the virus value of the multiplied virus suspension. The swine fever live vaccine disclosed by the invention can 100% protect the attack of swine fever strong virus.

The invention discloses a production method of a pseudorabies virus vaccine. The production method comprises the following steps: (1) adopting a cell of a continuous cell line, subjecting the cell to digestive passage, and continuously culturing the cell in a cell culture flask by using a cell growth medium; (2) diluting a virus seed into 10 times by using a cell maintenance medium, and inoculating a cell monolayer to obtain an infected cell virus liquid, that is, a virus seed for production; (3) preparing the cell monolayer formed in the step (1) into a cell suspension through digestion, inoculating the cell suspension into a bioreactor, and adding a microcarrier into the bioreactor; (4) performing virus-introduction operation on the cell, wherein the introduced virus seed is the virus seed produced in the step (2); and (5) harvesting liquid in the reactor together with the microcarrier until all of the cells on the microcarrier fall off and a dissolved oxygen value increases obviously, placing the liquid and the microcarrier under conditions of minus 20 DEG C, repeatedly freezing and thawing the liquid and the microcarrier twice, and removing the microcarrier and cell fragments to prepare the pseudorabies virus vaccine. The production method of the pseudorabies virus vaccine is short in production cycle and large in yield.

Monoclonal antibodies to Prox1 of vertebrates (pfam05044.5; NM_002763.3) and two continuous cell lines for their production are disclosed. These antibodies are particularly useful in immunoassays to detect the presence of Prox1 protein in vertebrate tissues and cells.

The invention discloses a method for culturing gosling plague virus by use of a goose embryo continuous cell line and a bioreactor, belonging to the technical field of veterinary biological products. The method comprises the following steps of: 1) culture of master cells; 2) suspension culture of cells for virus reproduction; and 3) culture and harvesting of virus. The method disclosed by the invention can shorten the production period and reduce personnel allocation, and realizes low pollution probability and small floor area; and the obtained virus has high titer and small inter-batch difference.

The invention discloses a method for culturing a chlamys farreri trochophore cell line. A small amount of nutrient factors for keeping cell metabolism are added in a special cell culture medium for chlamys farreri trochophore, so that the good growth state of chlamys farreri trochophore larva in vitro culture cells is realized, and the stable subcultring of the cells can be realized along with cell division. The method is simple to operate and low in cost; the complete dissociation of the cells is realized by use of the combination of soaking in a special calcium-free sea-water iso-osmia buffer solution for the chlamys farreri trochophore and a mechanical method, without any digestion by enzymes; the method is little in damage of the chlamys farreri trochophore larva in vitro culture cells, low in cost, high in efficiency and repeatable; a stable marine invertebrate cell in vitro culture method is established and can realize the in vitro multiplication and the subcultring of the cell, the chlamys farreri trochophore cell line is the first continuous cell line of marine shells, and the method has an important guiding significance for cell line establishment of other shells except the chlamys farreri.